Inhibrx Inc logo

Inhibrx Inc

NAS:INBX (USA)   Ordinary Shares
$ 34.28 -0.17 (-0.49%) 01:14 PM EST
At Loss
P/B:
37.26
Volume:
80.36K
Avg Vol (2M):
524.98K
Volume:
80.36K
At Loss
Avg Vol (2M):
524.98K
PE Ratio PS Ratio PB Ratio Price-to-FCF Market Cap
Current and historical daily PE Ratio for Inhibrx Inc ( ) from 2020 to Apr 19 2024. The price to earnings ratio is calculated by taking the current stock price and dividing it by the most recent trailing twelve-month earnings per share (EPS) number. The data is updated every 20 minutes during market hours. The PE ratio can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. Therefore, lower-P/E stocks are more attractive than higher P/E stocks so long as the PE ratio is positive. Also for stocks with the same PE ratio, the one with faster growth business is more attractive. Inhibrx stock (INBX) PE ratio as of Apr 19 2024 is 0. More Details

Inhibrx Inc (INBX) PE Ratio (TTM) Chart

To

Inhibrx Inc (INBX) PE Ratio (TTM) Historical Data

Total 927
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 11
Inhibrx PE Ratio (TTM) Historical Data
Date PE Ratio (TTM) Data Date PE Ratio (TTM) Data
2024-04-19 At Loss 2024-02-16 At Loss
2024-04-18 At Loss 2024-02-15 At Loss
2024-04-17 At Loss 2024-02-14 At Loss
2024-04-16 At Loss 2024-02-13 At Loss
2024-04-15 At Loss 2024-02-12 At Loss
2024-04-12 At Loss 2024-02-09 At Loss
2024-04-11 At Loss 2024-02-08 At Loss
2024-04-10 At Loss 2024-02-07 At Loss
2024-04-09 At Loss 2024-02-06 At Loss
2024-04-08 At Loss 2024-02-05 At Loss
2024-04-05 At Loss 2024-02-02 At Loss
2024-04-04 At Loss 2024-02-01 At Loss
2024-04-03 At Loss 2024-01-31 At Loss
2024-04-02 At Loss 2024-01-30 At Loss
2024-04-01 At Loss 2024-01-29 At Loss
2024-03-29 At Loss 2024-01-26 At Loss
2024-03-28 At Loss 2024-01-25 At Loss
2024-03-27 At Loss 2024-01-24 At Loss
2024-03-26 At Loss 2024-01-23 At Loss
2024-03-25 At Loss 2024-01-22 At Loss
2024-03-22 At Loss 2024-01-19 At Loss
2024-03-21 At Loss 2024-01-18 At Loss
2024-03-20 At Loss 2024-01-17 At Loss
2024-03-19 At Loss 2024-01-16 At Loss
2024-03-18 At Loss 2024-01-15 At Loss
2024-03-15 At Loss 2024-01-12 At Loss
2024-03-14 At Loss 2024-01-11 At Loss
2024-03-13 At Loss 2024-01-10 At Loss
2024-03-12 At Loss 2024-01-09 At Loss
2024-03-11 At Loss 2024-01-08 At Loss
2024-03-08 At Loss 2024-01-05 At Loss
2024-03-07 At Loss 2024-01-04 At Loss
2024-03-06 At Loss 2024-01-03 At Loss
2024-03-05 At Loss 2024-01-02 At Loss
2024-03-04 At Loss 2024-01-01 At Loss
2024-03-01 At Loss 2023-12-29 At Loss
2024-02-29 At Loss 2023-12-28 At Loss
2024-02-28 At Loss 2023-12-27 At Loss
2024-02-27 At Loss 2023-12-26 At Loss
2024-02-26 At Loss 2023-12-22 At Loss
2024-02-23 At Loss 2023-12-21 At Loss
2024-02-22 At Loss 2023-12-20 At Loss
2024-02-21 At Loss 2023-12-19 At Loss
2024-02-20 At Loss 2023-12-18 At Loss
2024-02-19 At Loss 2023-12-15 At Loss

Inhibrx Inc (INBX) PE Ratio (TTM) Comparison

Company Market Cap(Mil) PE Ratio (TTM)

Business Description

Business Description

Inhibrx Inc logo
Inhibrx Inc
NAICS : 325412 SIC : 2834
ISIN : US45720L1070

Share Class Description:

INBX: Ordinary Shares
Description
Inhibrx Inc is a clinical-stage biotechnology company focused on developing a pipeline of novel biologic therapeutic candidates. It combines an understanding of target biology with protein engineering, proprietary discovery technologies, and an integrative approach to research and development to design differentiated therapeutic candidates. The company has four programs in clinical trials, of which three of the programs are for the treatment of various cancers, and one for the treatment of Alpha-1 Antitrypsin Deficiency.